-
Pfizer announces Phase 3 clinical results of abrocitinib, a new-generation oral JAK1 inhibitor
Time of Update: 2021-04-19
(100mg, 200mg, once a day, orally), positive control drug dupilumab (300mg, baseline 600mg loading dose, once every 2 weeks, subcutaneous injection), placebo efficacy and safety, all patients received topical therapy.
-
China's latest consensus on diagnosis and treatment of central nervous system infections released, 3 minutes to focus
Time of Update: 2021-04-19
Recommendations: ➤ For patients with high suspicion of intracranial infection, CT or MRI is recommended to assist in diagnosis and treatment (medium level, strong recommendation).
-
quarter of 2021, 3 new drugs listed in urgent need of clinical overseas new drugs
Time of Update: 2021-04-19
In China, the drug's marketing application was accepted by CDE in February 2021, and was subsequently included in the priority review for the indication β-thalassemia.
-
K drug treatment of high-risk early triple-negative breast cancer encounters a complete response letter from the US FDA
Time of Update: 2021-04-19
The sBLA seeks to approve Keytruda for the treatment of high-risk early triple-negative breast cancer (TNBC) patients, specifically: Keytruda combined with chemotherapy for neoadjuvant (preoperative) treatment, and then Keytruda as a single drug for adjuvant (postoperative) treatment.
-
The FDA approves 5 CAR-T therapies in a row, and 3 domestic R&D models are in progress
Time of Update: 2021-04-18
>Ruijilunsai injection (ie JWCAR029) is a CAR-T product independently developed by WuXi Juno based on Juno's lisocabtagene maraleucel (liso-cel, JCAR017). In June 2020, the National Medical Products Administration of China
-
3 minutes to focus on blood pressure management in patients with acute ischemic stroke and heart disease|Guideline consensus
Time of Update: 2021-04-18
The annual incidence of stroke in my country is 250/100,000, and the annual incidence of coronary heart disease events is 50/100,000. Stroke and coronary heart disease
-
Both pictures and texts, teach you how to treat "hemorrhoids" under endoscopy (3)
Time of Update: 2021-04-18
and prolapse); 2. Hemorrhoids in stage I-III are ineffective in diet and drug treatment; 3. Recurrence after internal hemorrhoid surgery, but not after repeated anal surgery Surgery again; 4. Fear of surgery, unwilling
-
"K drug" single-agent adjuvant treatment of renal cell carcinoma phase III study yields positive
Time of Update: 2021-04-18
CCR: Androgen deprivation therapy combined with piperacillil does not improve RB-positive metastasis Sex hormone-sensitive prostate cancer prognosis JTO: Anti-PD-1 monoclonal antibody combination regimen has better survival results in the first-line treatment of advanced non-small cell lung cancer.
-
BeiGene Announces Global Phase 3 Clinical Interim Analysis Results of Baizean® in the Treatment of Second- and Third-Line Non-Small Cell Lung Cancer
Time of Update: 2021-04-18
On April 13, BeiGene (Nasdaq code: BGNE; Hong Kong Stock Exchange code: 06160) announced its anti-PD-1 antibody Bazeran® at the American Association for Cancer Research (AACR) 2021 annual meeting (Tilelizumab
-
The results of the first phase 3 study of the first-line immunotherapy for gastric cancer in China
Time of Update: 2021-04-18
> The Chinese subgroup data of the CheckMate-649 study strengthens our confidence in promoting the continuous development of gastric cancer and gastroesophageal junction cancer immunotherapy, and is expected to comprehensively
-
The detailed data of the Phase 3 clinical trial of Kexing inactivated vaccine is announced
Time of Update: 2021-04-18
The results of this test showed that the protective effect of two doses of CoronaVac on symptomatic COVID-19 reached 50.
-
Pfizer abrocitinib and Xeljanz review delayed by FDA for 3 months
Time of Update: 2021-04-18
In addition, the FDA has extended the review period of the supplementary new drug application (sNDA) for the oral anti-inflammatory drug Xeljanz/Xeljanz XR (tofacitinib, tofacitinib) for the treatment of adult patients with active ankylosing spondylitis (AS) by 3 months.
-
Express | Blockbuster PD-1 inhibitors in the treatment of early stage lung cancer reach the phase 3
Time of Update: 2021-04-18
▎The content team editor of WuXi AppTec recently, Bristol-Myers Squibb (BMS) announced that its blockbuster PD-1 inhibitor Odivo (Navulimab) is combined with chemotherapy to treat patients with early-stage non-small cell lung cancer Positive results at the time.
-
Lancet Neurology: Phase 3 clinical trial of onasmonogene abeparvovec in the treatment of symptomatic infantile spinal muscular atrophy
Time of Update: 2021-04-17
The Lancet Neurology, Volume 20, Issue 4, 284-293 Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
-
Announcement of the Jiangsu Provincial Market Supervision Bureau on the unqualified status of 3 batches of food (21st issue of 2021)
Time of Update: 2021-04-17
html" class="zdbq" title="Food information related to national food safety standards" target="_blank">national food safety standard inspection and judgment, 297 qualified samples and 3 batches of unqualified samples were foodmate.
-
JAHA: The relationship between plasma omega-3 fatty acids and the risk of cardiovascular events in patients with acute coronary syndrome
Time of Update: 2021-04-17
In patients with acute coronary syndrome , long-chain ω3-PUFA in plasma is negatively correlated with the reduced probability of sudden cardiac death, but has nothing to do with traditional risk factors and blood lipids.
-
Guoquan has 5,000 stores in 3 years, and the 400 billion yuan market battle royale
Time of Update: 2021-04-16
After comparing Daily Youxian and Guoquan, the new consumption of Guanchao found that the prices of conventional hot pot ingredients of the two are basically the same.
-
Analysis of my country's medical insurance fund supervision system, these 3 points are very important!
Time of Update: 2021-04-14
